HC Wainwright Has Positive Outlook of TNYA FY2026 Earnings

by · The Cerbat Gem

Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Free Report) – Analysts at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for Tenaya Therapeutics in a note issued to investors on Thursday, August 6th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.37) per share for the year, up from their prior forecast of ($0.51). The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Tenaya Therapeutics’ FY2027 earnings at ($0.35) EPS and FY2028 earnings at ($0.42) EPS.

Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.13). The business had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $10.00 million.

A number of other research analysts have also issued reports on TNYA. Wall Street Zen lowered Tenaya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 6th. Weiss Ratings raised shares of Tenaya Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $4.00.

Read Our Latest Stock Report on TNYA

Tenaya Therapeutics Stock Performance

TNYA opened at $0.75 on Monday. The company has a market capitalization of $168.46 million, a PE ratio of -1.42 and a beta of 2.83. The stock’s fifty day moving average is $0.77 and its 200-day moving average is $0.76. Tenaya Therapeutics has a one year low of $0.53 and a one year high of $2.35.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Scientech Research LLC purchased a new stake in Tenaya Therapeutics in the 3rd quarter worth approximately $27,000. Integrity Wealth Solutions LLC purchased a new position in shares of Tenaya Therapeutics during the 1st quarter valued at $27,000. Callan Family Office LLC acquired a new position in shares of Tenaya Therapeutics in the second quarter worth $37,000. Comerica Bank acquired a new position in shares of Tenaya Therapeutics in the first quarter worth $50,000. Finally, Cerity Partners LLC raised its holdings in shares of Tenaya Therapeutics by 403.5% during the second quarter. Cerity Partners LLC now owns 110,336 shares of the company’s stock worth $67,000 after acquiring an additional 88,424 shares in the last quarter. Institutional investors and hedge funds own 90.54% of the company’s stock.

Tenaya Therapeutics Company Profile

(Get Free Report)

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.

Featured Articles